NeuroSense Therapeutics Schedules Shareholder Meeting
Ticker: NRSNW · Form: 6-K · Filed: May 28, 2024 · CIK: 1875091
| Field | Detail |
|---|---|
| Company | Neurosense Therapeutics LTD. (NRSNW) |
| Form Type | 6-K |
| Filed Date | May 28, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting, filing-update
TL;DR
NeuroSense set June 27th for shareholder meeting, proxy docs filed.
AI Summary
NeuroSense Therapeutics Ltd. filed a Form 6-K on May 28, 2024, to report information for the month of May 2024. The filing includes a Notice and Proxy Statement for their Annual General Meeting of Shareholders scheduled for June 27, 2024, and a Proxy Card.
Why It Matters
This filing signals upcoming corporate decisions and governance activities that could impact the company's strategic direction and shareholder value.
Risk Assessment
Risk Level: low — The filing is routine corporate disclosure and does not contain new financial or operational risks.
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Registrant
- June 27, 2024 (date) — Annual General Meeting date
- May 28, 2024 (date) — Filing date
FAQ
What is the purpose of the Form 6-K filing?
The Form 6-K is filed by NeuroSense Therapeutics Ltd. to report information for the month of May 2024, specifically including a Notice and Proxy Statement for their Annual General Meeting of Shareholders and a Proxy Card.
When is the Annual General Meeting of Shareholders scheduled?
The Annual General Meeting of Shareholders for NeuroSense Therapeutics Ltd. is scheduled for June 27, 2024.
What exhibits are included with this Form 6-K?
This Form 6-K includes Exhibit 99.1 (Notice and Proxy Statement for the Annual General Meeting of Shareholders) and Exhibit 99.2 (Proxy Card).
What is the company's principal executive office address?
The company's principal executive offices are located at 11 HaMenofim Street, Building B, Herzliya 4672562, Israel.
Does NeuroSense Therapeutics file annual reports under Form 20-F or Form 40-F?
NeuroSense Therapeutics indicates that it files annual reports under Form 20-F.
Filing Stats: 241 words · 1 min read · ~1 pages · Grade level 12 · Accepted 2024-05-28 07:14:29
Filing Documents
- ea0206851-6k_neurose.htm (6-K) — 10KB
- ea020685101ex99-1_neurose.htm (EX-99.1) — 102KB
- ea020685101ex99-2_neurose.htm (EX-99.2) — 2KB
- ex99-1_001.jpg (GRAPHIC) — 9KB
- ex99-2_001.jpg (GRAPHIC) — 735KB
- ex99-2_002.jpg (GRAPHIC) — 509KB
- 0001213900-24-046796.txt ( ) — 1841KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: May 28, 2024 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 2